slides · global inventory
Problem Agitate Solve Pas
Tool collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 1,125
Current window 751-780
Pages 38
Rows per page 30
Tool
751-780 of 1,125
20
The slide uses a high-contrast green background and a photo of scientists to emphasize the 'From Target to Drug' workflow.AbCellera | Investor Presentation Deck | 21 slides · AbCellera
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
07
The diagram shows a circular, inefficient optimization process (affinity, developability, toxicity) leading to suboptimal candidates.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
106
The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
04
Uses a process diagram to illustrate the iterative, inefficient nature of traditional drug discovery.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
04
Uses a process diagram to illustrate the iterative, inefficient nature of traditional drug discovery.Absci | Investor Presentation Deck | 48 slides · Absci
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a three-column layout to present the company's core technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
24
The chart compares benchmark induction remission rates with vedolizumab exposure quartiles.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
The slide uses a three-column layout to explain the scientific basis and product advantages.Arbutus Biopharma | Investor Presentation Deck | 25 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
23
Includes a map of global disease burden and key product specs.ATAI | Investor Presentation Deck | 31 slides · atai Life Sciences
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
03
The slide uses a value-chain style diagram to illustrate the complexity of the ad-tech landscape.Azerion | Investor Conference Presentation Deck | 31 slides · Azerion
Conference presentation Investor relations Beat · ProblemLoop · Logic Chain1 hit
34
Includes an in vitro cell viability dose-response curve and a pharmacokinetic (PK) model showing plasma concentration over time.Chimerix | Investor Presentation Deck | 43 slides · Chimerix
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
06
Highlights the repurposing of the active ingredient in Viagra for a new indication with no current FDA-approved treatments.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The slide uses a visual contrast between negative outcomes (down arrows) and positive outcomes (up arrow for customer satisfaction).Deliveroo | Results Presentation Deck | 27 slides · Deliveroo
Conference presentation Investor relations Beat · Action1 hit
10
The slide uses a visual comparison to frame the problem of 'too narrow' vs 'too broad' inhibition.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
09
Etsy | Results Presentation Deck | 42 slidesEtsy | Results Presentation Deck | 42 slides · Etsy
Conference presentation Investor relations Beat · Interest1 hit
57
Eutelsat | Investor Presentation Deck | 70 slidesEutelsat | Investor Presentation Deck | 70 slides · Eutelsat
Conference presentation Investor relations 1 hit
47
Includes two scientific citations for the mechanism and brain penetration.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
58
The slide uses a three-column layout to summarize the value proposition of the drug candidate.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle1 hit
62
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Exscientia | Investor Presentation Deck | 75 slidesExscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
64
Exscientia | Investor Presentation Deck | 75 slidesExscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
11
FiscalNote | Investor Presentation Deck | 32 slidesFiscalNote | Investor Presentation Deck | 32 slides · FiscalNote
Pitch deck Investor relations Beat · ProductLoop · Quick Win Big Bet1 hit
11
The slide uses a three-part categorization to outline operational and digital improvements.Heartland Financial USA | Results Presentation Deck | 53 slides · HTLF
Conference presentation Investor relations Beat · Rising SuccessLoop · Cost Of Inaction1 hit
08
Includes a cartoon liver character, likely representing the target organ or safety profile.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
19
The slide uses a process diagram to show the self-assembly of lipoplexes into PS-NPs.Matinas BioPharma | Investor Presentation Deck | 28 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
12
The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
07
Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's success.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
The slide uses a medical illustration to map specific TRK receptor inhibition side effects to anatomical locations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
19
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
The slide uses a split-pane layout: left side for problem/market context, right side for product solution.Nuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit